Bookmark and Share
BioAssay: AID 588498

qHTS profiling assay for firefly luciferase inhibitor/activator using purifed enzyme and Km concentrations of substrates (counterscreen for the Campaign to Identify EBNA-1 Inhibitors project).

Firefly (Photinus pyralis) luciferase is one of the most commonly used transcriptional reporters for a number of reasons. It is considered one of the more dynamically responsive reporters -that is, responsive to changes in reporter transcription - as it requires no post-translational modifications and is enzymatically active directly after protein synthesis (Wood, 1998). Additionally, the more ..
_
   
 Tested Compounds
 Tested Compounds
All(20)
 
 
Active(18)
 
 
Inactive(2)
 
 
 Tested Substances
 Tested Substances
All(20)
 
 
Active(18)
 
 
Inactive(2)
 
 
AID: 588498
Data Source: Molecular Libraries Program, Specialized Chemistry Center, University of Kansas (KUA10011)
BioAssay Type: Confirmatory, Concentration-Response Relationship Observed
Depositor Category: NIH Molecular Libraries Probe Production Network
BioAssay Version:
Deposit Date: 2011-10-12
Hold-until Date: 2011-10-18
Modify Date: 2011-10-18

Data Table ( Complete ):           View Active Data    View All Data
Target
BioActive Compounds: 18
Related Experiments
Show more
AIDNameTypeComment
1950Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the Epstein-Barr virus nuclear antigen 1 (EBNA-1).Screeningdepositor-specified cross reference
1955Summary of probe development efforts to identify inhibitors of the Epstein-Barr virus nuclear antigen 1 (EBNA-1).Summarydepositor-specified cross reference
2234Counterscreen for inhibitors of EBNA-1: fluorescence polarization-based biochemical high throughput primary assay to identify inhibitors of the Epstein-Barr virus-encoded protein, ZTA.Screeningdepositor-specified cross reference
2292Fluorescence polarization-based biochemical high throughput confirmation assay to identify inhibitors of the Epstein-Barr virus nuclear antigen 1 (EBNA-1).Screeningdepositor-specified cross reference
2374PAK-Effector Pull-down Assay for Quantification of Rac/Cdc42 Activation Using 3T3 CellsOtherdepositor-specified cross reference
2381Fluorescence polarization-based biochemical high throughput dose response assay for inhibitors of the Epstein-Barr virus nuclear antigen 1 (EBNA-1)Confirmatorydepositor-specified cross reference
488998Late stage counterscreen results for the probe development effort to identify inhibitors of the Epstein-Barr virus nuclear antigen 1 (EBNA-1): fluorescence polarization-based biochemical dose response assay for inhibitors of the Epstein-Barr virus-encoded protein, ZTAConfirmatorydepositor-specified cross reference
493077Late stage assay provider counterscreen results for the probe development effort to identify inhibitors of the Epstein-Barr virus nuclear antigen 1 (EBNA-1): Fluorescence polarization-based biochemical dose response assay for inhibitors of the Epstein-Barr virus-encoded protein, ZTAConfirmatorydepositor-specified cross reference
493079Late stage assay provider results for the probe development effort to identify inhibitors of the Epstein-Barr virus nuclear antigen 1 (EBNA-1): Fluorescence polarization-based biochemical dose response assay for EBNA-1 inhibitorsConfirmatorydepositor-specified cross reference
2328Counterscreen for inhibitors of EBNA-1: fluorescence polarization-based biochemical high throughput assay for inhibitors of the Epstein-Barr virus-encoded protein, ZTA, in triplicate.Screeningsame project related to Summary assay
2361Fluorescence polarization-based biochemical high throughput confirmation assay for inhibitors of the Epstein-Barr virus-encoded protein, ZTAScreeningsame project related to Summary assay
2362Counterscreen for inhibitors of ZTA: fluorescence polarization-based biochemical high throughput assay to identify inhibitors of the Epstein-Barr virus nuclear antigen 1 (EBNA-1)Screeningsame project related to Summary assay
2377Counterscreen for inhibitors of EBNA-1: fluorescence polarization-based biochemical high throughput dose response assay to identify inhibitors of the Epstein-Barr virus-encoded protein, ZTAConfirmatorysame project related to Summary assay
489000Late stage results for the probe development effort to identify inhibitors of the Epstein-Barr virus nuclear antigen 1 (EBNA-1): Fluorescence polarization-based biochemical dose response assay for EBNA-1 inhibitorsConfirmatorysame project related to Summary assay
588762Late stage assay provider results for the probe development effort to identify inhibitors of the Epstein-Barr virus nuclear antigen 1 (EBNA-1): Cell-based luciferase-based dose response assay for EBNA-1 inhibitorsConfirmatorysame project related to Summary assay
Description:
MLPCN Grant: 1 R21 NS063906-01 (Campaign to Identify EBNA-1 Inhibitors grant)

Assay Provider: NCGC

NCGC Assay Overview:

Firefly (Photinus pyralis) luciferase is one of the most commonly used transcriptional reporters for a number of reasons. It is considered one of the more dynamically responsive reporters -that is, responsive to changes in reporter transcription - as it requires no post-translational modifications and is enzymatically active directly after protein synthesis (Wood, 1998). Additionally, the half-life of the luciferase protein is short relative to other reporter-gene products (Wood, 1995). Whereas reporters with long half-lives potentially allow for increased signal due to accumulation of reporter-gene product, once accumulated in the cell, dynamic changes in reporter-gene expression may be difficult to detect(Fan and Wood, 2007; Almond et al., 2004). It has been shown that wild-type P. pyralis luciferase has a half-life of approximately four hours in mammalian cells (Thompson et al., 1991). Firefly luciferase reporter-gene assays are also generally considered one of the most sensitive assay types (Wood, 1995; Wood, 1998). Although light produced in a bioluminescence reaction is of lower intensity than that produced during fluorescence emission[52], this is offset by little to no background light inherent to luminescent assays. Thus the luciferase reporter can be expressed at much lower levels than fluorescent proteins while still providing robust signal.
However, it was initially observed, in 1991, by Thompson et al., that compounds that resemble the substrates of firefly luciferase (FLuc) can act as competitive inhibitors of the enzyme, and that these compounds, upon interaction with luciferase in the cell, can actually stabilize the protein and increase its half-life. Accumulated intracellular FLuc protein can be measured as an increase in luminescence signal, upon addition of detection reagents (which contain high concentrations of FLuc substrates) commonly used in high-throughput screening.
In cell-based reporter gene assays that use FLuc as the reporter gene to quantitate the potential influence of a given compound against the target biology, this apparent increase in luminescence can mistakenly be interpreted as identification of a compound that is active against the target of interest. This is the case for the EBNA-1 FLuc reporter gene assay used to identify inhibitors of EBNA-1 (PubChem AID 1995) - compounds of interest will inhibit EBNA-1, and are identified by causing an increase in luminescence, due to increased FLuc translation. However, FLuc inhibitory compounds that stabilize the FLuc protein will give an identical read-out, making it difficult to distinguish compounds that are active against the target from those active against FLuc.
Previous profiling work to determine the prevalence of compounds that affect FLuc enzymatic activity (PubChem AID 411) identified that ~3% of the MLSMR library (then at ~72K) inhibited FLuc. Analysis of cell-based FLuc reporter gene assays posted in PubChem indicated that as many as 60% of the actives identified in a given screen using this type of assay were actually FLuc inhibitors (Auld et al., 2008). Since several of the EBNA1 hits and resulting analogs belonged to chemotypes or similar chemotypes that had been shown previously to interfere with the FLuc assay, a subset of these were selected for activity against FLuc using a biochemical assay of purified FLuc and KM concentrations of FLuc substrates (D-luciferin and ATP).
Protocol
NCGC Assay Protocol Summary:

Reagents: 50mM Tris acetate, pH 7.5; 10mM Mg acetate; 10uM D-luciferin (Sigma #L9504); 10uM ATP; 0.01% Tween-20; 0.05% BSA; 10nM P. pyralis luciferase (Sigma #L9506)
Control compounds used were two known firefly luciferase inhibitors (compounds (2) and (5) in Auld et al., 2010), and DMSO.

Assay Summary:
Three microliters containing firefly luciferase substrates in buffer (final concentrations: 50mM Tris acetate, pH 7.5, 10mM Mg acetate, 0.01% Tween-20, 0.05% BSA, 10uM D-luciferin, and 10uM ATP) are dispensed into each well of a Greiner white, solid-bottom 1536-well format plate using a flying reagent dispenser (FRD). These assay plates were then treated with 23nL of compound or DMSO using a Kalypsys pin tool, which allows for delivery of a 6-point interplate titration of each compound to the assay plate (quantitative HTS), with a final compound concentrations ranging from approximately 60muM to 7pM. One microliter of firefly luciferase in 500mM Tris-acetate buffer was then delivered by FRD to each well for a final enzyme concentration of 10nM. Luciferase activity was then measured using a ViewLux CCD imager (PerkinElmer), with an average exposure time of 2-30 seconds (2X binning, medium/high gain).

Keywords: NIH Roadmap, MLPCN, MLSMR, qHTS, miR-21, firefly luciferase, FLuc, miRNA.
Comment
Compunds idenfied as firefly luciferase inhibitors are reported as active in this assay. Compounds were ranked based on the following criteria. All inactive compounds, PUBCHEM_ACTIVITY_SCORE is between 0 and 30 (potency > 20 uM). Active compounds have PUBCHEM_ACTIVITY_SCORE between 30 and 100 (potency < 20 uM). Potency was used for determining the relative PubChem score.
Categorized Comment - additional comments and annotations
From ChEMBL:
Assay Type: Functional
Result Definitions
Show more
TIDNameDescriptionHistogramTypeUnit
OutcomeThe BioAssay activity outcomeOutcome
ScoreThe BioAssay activity ranking scoreInteger
1Potency*Concentration at which compound exhibits half-maximal efficacy, AC50. Extrapolated AC50s also include the highest efficacy observed and the concentration of compound at which it was observed.FloatμM
2EfficacyMaximal efficacy of compound, reported as a percentage of control. These values are estimated based on fits of the Hill equation to the dose-response curves.Float%
3Fit_LogAC50The logarithm of the AC50 from a fit of the data to the Hill equation (calculated based on Molar Units).Float
4Fit_HillSlopeThe Hill slope from a fit of the data to the Hill equation.Float
5Fit_R2R^2 fit value of the curve. Closer to 1.0 equates to better Hill equation fit.Float
6Fit_InfiniteActivityThe asymptotic efficacy from a fit of the data to the Hill equation.Float%
7Fit_ZeroActivityEfficacy at zero concentration of compound from a fit of the data to the Hill equation.Float%
8Fit_CurveClassNumerical encoding of curve description for the fitted Hill equation.Float
9Max_ResponseMaximum activity observed for compound (usually at highest concentration tested).Float%
10Activity at 0.000324 uM (0.000324μM**)% Activity at given concentration.Float%
11Activity at 0.000973 uM (0.000973μM**)% Activity at given concentration.Float%
12Activity at 0.00291 uM (0.00291μM**)% Activity at given concentration.Float%
13Activity at 0.00875 uM (0.00875μM**)% Activity at given concentration.Float%
14Activity at 0.0788 uM (0.0788μM**)% Activity at given concentration.Float%
15Activity at 0.236 uM (0.236μM**)% Activity at given concentration.Float%
16Activity at 0.709 uM (0.709μM**)% Activity at given concentration.Float%
17Activity at 2.128 uM (2.128μM**)% Activity at given concentration.Float%
18Activity at 6.385 uM (6.385μM**)% Activity at given concentration.Float%
19Activity at 19.157 uM (19.157μM**)% Activity at given concentration.Float%
20Activity at 57.471 uM (57.471μM**)% Activity at given concentration.Float%

* Activity Concentration. ** Test Concentration.
Additional Information
Grant Number: 1 R21 NS059478-01

Data Table (Concise)
Data Table ( Complete ):     View Active Data    View All Data
PageFrom: